Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 1/20 | 0.57 |
| ▸ | PGR | P06401 | 2/20 | 0.55 |
| ▸ | FABP4 | P15090 | 10/20 | 0.50 |
| ▸ | FABP5 | Q01469 | 6/20 | 0.50 |
| ▸ | RORC | P51449 | 1/20 | 0.50 |
| ▸ | IDH1 | O75874 | 1/20 | 0.49 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.48 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.48 |
| ▸ | BRAF | P15056 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | WDR5 | P61964 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6714314 | 0.85 | SLC22A12 (0.65) | FABP4FABP5BRAFWDR5 | |
| SCHEMBL3617602 | 0.83 | TET2 (0.57) | FABP4FABP5WDR5 | |
| SCHEMBL6710070 | 0.78 | CDK1 (0.59) | FABP4FABP5IDH1FFAR1FFAR4 | |
| SCHEMBL3622402 | 0.78 | FABP4 (0.58) | FABP4FABP5FFAR1FFAR4MEN1 | |
| SCHEMBL5531152 | 0.77 | FABP4 (0.53) | FABP4FABP5IDH1KMT2A | |
| SCHEMBL31034706 | 0.77 | CA1 (0.57) | ACLYPGRIDH1FFAR1FFAR4 | |
| SCHEMBL6087557 | 0.77 | CA1 (0.57) | ACLYPGRIDH1FFAR1FFAR4 | |
| SCHEMBL3622423 | 0.76 | FABP4 (0.54) | ACLYFABP4FABP5 | |
| Hydrochloric Acid SCHEMBL6766422 | 0.76 | FABP4 (0.52) | FABP4FABP5IDH1KMT2A | |
| SCHEMBL3652105 | 0.75 | FABP4 (0.46) | FABP4FABP5WDR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1412325-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS, PROCESS FOR THEIR USE AS MEDICAMENT FOR THE TREATMENT OF CNS DISORDERS, OBESITY AND TYPE II DIABETES | BIOVITRUM AB (SE) | 2004-04-28 | — | — | EP | disclosed |
| WO-2002100822-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS, PROCESS FOR THEIR USE AS MEDICAMENT FOR THE TREATMENT OF CNS DISORDERS, OBESITY AND TYPE II DIABETES | BIOVITRUM AB (SE) | 2002-12-19 | — | — | WO | disclosed |